Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | SHBG | P04278 | 1/20 | 0.31 |
| ▸ | ADH1B | P00325 | 1/20 | 0.30 |
| ▸ | ADH1C | P00326 | 1/20 | 0.30 |
| ▸ | ADH1A | P07327 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15270726 | 1.00 | SLC2A1 (0.31) | SLC2A1SHBGADH1BADH1CADH1A | |
| SCHEMBL13081808 | 0.97 | — | — | |
| SCHEMBL4017588 | 0.91 | — | — | |
| SCHEMBL15271048 | 0.84 | — | — | |
| SCHEMBL7471909 | 0.78 | ADH1B (0.32) | ADH1BADH1CADH1A | |
| SCHEMBL7482713 | 0.78 | — | — | |
| SCHEMBL8699020 | 0.78 | — | — | |
| SCHEMBL7479908 | 0.76 | SLC2A1 (0.32) | SLC2A1 | |
| SCHEMBL22764106 | 0.76 | — | — | |
| SCHEMBL8700759 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4059699-A | O,O-diethyl-O-carboxamidophosphate esters and use to combat insects and mites | GULF OIL CORPORATION (US) | 1977-11-22 | — | — | US | claimed |
| US-3994997-A | MITICIDES, INSECTICIDES | GULF OIL CORPORATION (US) | 1976-11-30 | — | — | US | claimed |
| US-20230276701-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT EMISSION DEVICE | OSAKA UNIVERSITY (JP) | 2023-08-31 | — | — | US | disclosed |
| US-20230276701-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT EMISSION DEVICE | OSAKA UNIVERSITY (JP) | 2023-08-31 | — | — | US | disclosed |
| US-11358985-B2 | Tripeptide compound, preparation method therefor, and application thereof | NORTHWEST UNIVERSITY (CN) | 2022-06-14 | — | — | US | disclosed |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | NUVATION BIO INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-10442798-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2019-10-15 | — | — | US | disclosed |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-01-24 | — | — | US | disclosed |
| US-20180222856-A1 | SELECTIVE INHIBITORS OF CARBONIC ANHYDRASE | VILNIUS UNIVERSITY (LT) | 2018-08-09 | — | — | US | disclosed |
| US-20180208587-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2018-07-26 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20110281874-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-8022223-B2 | 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110034463-A1 | TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
| US-20090156603-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-4059699-A | O,O-diethyl-O-carboxamidophosphate esters and use to combat insects and mites | GULF OIL CORPORATION (US) | 1977-11-22 | — | — | US | disclosed |
| US-4059699-A | O,O-diethyl-O-carboxamidophosphate esters and use to combat insects and mites | GULF OIL CORPORATION (US) | 1977-11-22 | — | — | US | disclosed |
| US-3994997-A | MITICIDES, INSECTICIDES | GULF OIL CORPORATION (US) | 1976-11-30 | — | — | US | disclosed |
| US-3994997-A | MITICIDES, INSECTICIDES | GULF OIL CORPORATION (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | SLC2A1 3296/4885SHBG 1931/4885ADH1B 2478/4885 |
| US-11358985-B2 | Tripeptide compound, preparation method therefor, and application thereof | VIP, PREP, ACE | SLC2A1 2635/4885SHBG 1918/4885ADH1B 1760/4885 |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | SLC2A1 2020/4885SHBG 3759/4885ADH1B 2589/4885 |
| US-20180222856-A1 | SELECTIVE INHIBITORS OF CARBONIC ANHYDRASE | CA9, CA2, CA7 | SLC2A1 412/4885SHBG 2650/4885ADH1B 211/4885 |
| US-20110034463-A1 | TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF | GBA3, CLPP, PEX3 | SLC2A1 3863/4885SHBG 4181/4885ADH1B 4825/4885 |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | ADORA2A, ADORA3, ADORA1 | SLC2A1 2020/4885SHBG 3759/4885ADH1B 2589/4885 |
| US-20230276701-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT EMISSION DEVICE | ESR1, ECE1, ESYT1 | SLC2A1 4326/4885SHBG 2786/4885ADH1B 2998/4885 |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | SLC2A1 2020/4885SHBG 3759/4885ADH1B 2589/4885 |
| US-20090156603-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, PRKCSH | SLC2A1 33/4885SHBG 1539/4885ADH1B 572/4885 |
| US-10442798-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORA, RORC, RORB | SLC2A1 3758/4885SHBG 497/4885ADH1B 871/4885 |
| US-20180208587-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | RORA, RORB, RORC | SLC2A1 3981/4885SHBG 560/4885ADH1B 844/4885 |
| US-20110281874-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | SLC2A1 18/4885SHBG 3340/4885ADH1B 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.